About HPSC BioSeed
A World-Class Biotech Built on Decades of Science
HPSC BioSeed is a biotechnology company dedicated to the research, development, and commercialization of placental stem cell and exosome-based regenerative therapies. Our mission: advance next-generation cell technologies capable of addressing complex diseases through immune modulation, tissue regeneration, and precision cellular medicine.
Our Core Strengths
TWD 2 Billion Investment
Fully automated stem cell culture systems with real-time monitoring, sterile environment culture technology, and automated media replacement — meeting international GMP standards.
Southeast Asia Expansion
Biospring X (M) Sdn. Bhd. incorporated in Malaysia in February 2025 (Reg. No. 202501004960), bringing cutting-edge cell technology to the ASEAN market.
800+ Institution Network
Our research network spans over 800 participating institutions and 130+ specialists in stem cell biology, clinical research, biotechnology manufacturing, and medical management.
If the 20th century was the era of drug therapy, the 21st century will be the era of cell therapy.
George Daley
Dean, Harvard Medical School · Director, Stem Cell Transplantation Program, Boston Children's Hospital · President, ISSCR (2007–2008)
Scientific Edge
Comprehensive Research Infrastructure
Our research and development center integrates the most advanced bioprocessing technologies:
- Fully automated stem cell culture systems
- Real-time monitoring of cell growth conditions
- Sterile environment culture technology
- Automated media replacement systems
- Biosafety cabinets and CO₂ incubators
- Central control center and cell processing rooms
Our quality and compliance framework:
- Good Manufacturing Practices (GMP)
- Good Tissue Practice (GTP)
- Serum-Free Medium (SFM) culture systems
- Master Cell Bank (MCB) management
- Chemistry, Manufacturing & Controls (CMC)
- Institutional Review Board (IRB) oversight
Facility Overview — 2026